[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338250-105":59,"doc-detail-338250-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","comprehensive-analysis-to-identify-il7r-as-a-immunotherapy-biomarker-from-pan-cancer-analysis-to-in-vitro-validation","Comprehensive analysis to identify IL7R as a immunotherapy biomarker from pan-cancer analysis to in vitro validation","","Immunotherapy encounters major treatment resistance, making reliable efficacy biomarkers essential. The tumor microenvironment (TME) strongly affects outcomes, requiring molecular characterization of TME states to better address resistance mechanisms. This study first highlights IL7R as a key TME gene, then integrates single-cell, bulk-RNA, infiltration, and immunohistochemistry validation to connect IL7R biology with CD8+ T cell programs. Clinical cohort analyses further assess whether IL7R predicts immunotherapy benefit and survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comprehensive-analysis-to-identify-il7r-as-a-immunotherapy-biomarker-from-pan-cancer-analysis-to-in-vitro-validation/338250/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comprehensive-analysis-to-identify-il7r-as-a-immunotherapy-biomarker-from-pan-cancer-analysis-to-in-vitro-validation/338250.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why does this study focus on IL7R for immunotherapy biomarkers?","Question",{"text":112,"@type":113},"Treatment resistance in immunotherapy makes efficacy biomarker identification critical. The work targets IL7R as a pivotal TME gene and evaluates its associations with TME-related immune programs and clinical immunotherapy outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What methods were used to validate IL7R in the tumor microenvironment?",{"text":117,"@type":113},"The study combines single-cell analysis of IL7R effects on TME CD8+ T cells, bulk-RNA analysis of IL7R function and immune infiltration in pan-cancer cohorts, and immunohistochemistry verification in clinical samples. It also assesses genome instability and immune-related molecular expression linked to IL7R.",{"name":119,"@type":110,"acceptedAnswer":120},"Does high IL7R expression relate to better immunotherapy response?",{"text":121,"@type":113},"High IL7R expression is associated with non-terminal T cell features and favorable immunotherapy responses. Patients with high IL7R show increased immune and stromal signatures, immune pathway enrichment, a more immune-inflamed TME, and extended survival under immunotherapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338250,1790479114,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Research  \nComprehensive analysis to identify IL7R as a immunotherapy biomarker from pan‑cancer analysis to in vitro validation  \nJiafeng Liang1 · Lucheng Zhu1 · Jiawei Li1 · Kan Wu1 · Minna Zhang1 · Shenglin Ma1 · Xueqin Chen1 · Bing Xia1  \nReceived: 18 June 2024 / Accepted: 17 September 2024  \n© The Author(s) 2024 OPEN  \nAbstract  \nBackground Immunotherapy faces a major challenge in treatment resistance, highlighting the need for efficacy biomarkers identification. The tumor microenvironment (TME) significantly influences treatment outcomes, necessitating molecular TME exploration to address immunotherapy resistance.  \nMethods The study initially pinpointed IL7R as a pivotal TME gene and then examined its impact onTME’s CD8 + T cells at the single-cell level. Bulk-RNA analysis investigated IL7R function, immune cell infiltration related to IL7R in TCGApan-cancer samples with its expression verified in clinical samples through immunohistochemistry. Genome instability and immune-related molecular expression associated with IL7R were also assessed. Furthermore, the clinical efficacy of IL7R was evaluated in various immunotherapy treatment cohorts.  \nResults Our single-cell analyses and cell-cased experiment revealed that T cells with high IL7R expression tended to be non-terminal and correlated with favorable immunotherapy responses. High IL7R expression corresponded to increased immune and stromal cell signiture, immune pathway enrichment, and an immune-inflamed environment in Bulk-RNA analysis and immunohistochemistry verification. These patients exhibited higher proportions of memory T cells and M1 cells within the TME, along with frequent genome instability and immune molecular upregulation. While IL7R had varied prognostic impact across theTCGA dataset, patients with high IL7R expression showed extended survival under immunotherapy.  \nConclusion IL7R plays a critical role in shaping TME diversity across cancer types and holds promise as a relevant biomarker for predicting immunotherapy benefits.  \nKeywords Immunotherapy · Pan-cancer · Tumor microenvironment · T cell · IL7R  \n1 Introduction  \nThe 2010s have been characterized as the era of immunotherapy, with its application in a variety of cancers resulting in response rates of up to 20–50%, and some responders even achieving long-term survival [1–6] . However, only 10–60% of patients can benefit from immunotherapy [7], making responder screening crucial for efficient medical resources allocation.  \nSupplementary Information The online version contains supplementary material available at [https://doi.org/10.1007/s12672-024-](https://doi.org/10.1007/s12672-024-)[ ](https://doi.org/10.1007/s12672-024-)[01357-7](01357-7.)[.](01357-7.)  \n* Xueqin Chen, [chenxueqin@zju.edu.cn](chenxueqin@zju.edu.cn); * Bing Xia, [bingxia_hzch@163.com |](bingxia_hzch@163.com |1Department of Thoracic Oncology)[1](bingxia_hzch@163.com |1Department of Thoracic Oncology)[Department of Thoracic Oncology](bingxia_hzch@163.com |1Department of Thoracic Oncology), Hangzhou Cancer Hospital, Hangzhou 310002, China.  \nDiscover Oncology  \n(2024) 15:509  \n| [https://doi.org/10.1007/s12672-024-01357-7](https://doi.org/10.1007/s12672-024-01357-7)  \nFig. 1 IL7R function its role in non-exhausting T cells. A Venn diagram shows overlapping differentially expressed gene signatures in Immu- ▸ neScore-DEG and StromalScore-DEG. B Hub PPI network constructed according to DEGs. DEGs came from ImmuneScore and StromalScore DEGs sets intersection. C, D Boxplot shows IL7R expression in different CD8+ T cell subtypes in GSE120575 (C), GSE179994 (D) . E UMAP shows CD8+ T cell clusters. F UMAP shows IL7R expression in single CD8+ T cell. G UMAP shows IL7R expression across pseudotime. H RTPCR shows IL7R expression decreasing with T cells exhausting makers growing. I tSNE shows the patients’ response to immunotherapy. JtSNE shows IL7R expression in single CD8+ T cell  \nThe tumor microenvironment (TME) is one of the determinants","cbCaif2cww9K9or4","https://ap.wps.com/l/cbCaif2cww9K9or4","pdf",8100107,17,"English","# Abstract\n# Background\n# Methods\n## Data collection\n# Results\n# Conclusion\n# Keywords\n# Introduction","[{\"question\":\"Why does this study focus on IL7R for immunotherapy biomarkers?\",\"answer\":\"Treatment resistance in immunotherapy makes efficacy biomarker identification critical. The work targets IL7R as a pivotal TME gene and evaluates its associations with TME-related immune programs and clinical immunotherapy outcomes.\"},{\"question\":\"What methods were used to validate IL7R in the tumor microenvironment?\",\"answer\":\"The study combines single-cell analysis of IL7R effects on TME CD8+ T cells, bulk-RNA analysis of IL7R function and immune infiltration in pan-cancer cohorts, and immunohistochemistry verification in clinical samples. It also assesses genome instability and immune-related molecular expression linked to IL7R.\"},{\"question\":\"Does high IL7R expression relate to better immunotherapy response?\",\"answer\":\"High IL7R expression is associated with non-terminal T cell features and favorable immunotherapy responses. Patients with high IL7R show increased immune and stromal signatures, immune pathway enrichment, a more immune-inflamed TME, and extended survival under immunotherapy.\"}]","Comprehensive analysis to identify IL7R as a immunotherapy biomarker from pan-cancer analysis to in vitro validation | PDF",1790022752,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1208cc61753c42b9226b46bc957f4f3b.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/254de08c2d899b39dde1045e798d01ad.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e4e010cde024b97683c859edeb864fa.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05bcc278809bd8b3b2e27404d797536b.webp",980,1301]